ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of “Moderate Buy” by Analysts

ArriVent BioPharma, Inc. (NASDAQ:AVBP) has been given an average rating of “Moderate Buy” by the nine analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $39.1429.

Several equities research analysts have recently commented on AVBP shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a research report on Saturday, September 27th. Guggenheim reaffirmed a “buy” rating and issued a $45.00 price objective on shares of ArriVent BioPharma in a research report on Tuesday, June 24th. Citigroup reaffirmed a “buy” rating and issued a $33.00 price objective (down from $40.00) on shares of ArriVent BioPharma in a research report on Tuesday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $42.00 price objective (up from $40.00) on shares of ArriVent BioPharma in a research report on Tuesday, August 12th. Finally, B. Riley raised shares of ArriVent BioPharma to a “strong-buy” rating in a research report on Monday, August 25th.

ArriVent BioPharma Price Performance

NASDAQ:AVBP opened at $19.84 on Monday. The firm has a 50-day moving average of $18.95 and a 200-day moving average of $20.08. The company has a market cap of $804.89 million, a PE ratio of -4.94 and a beta of 1.11. ArriVent BioPharma has a one year low of $15.47 and a one year high of $36.37.

ArriVent BioPharma (NASDAQ:AVBP) last posted its earnings results on Monday, August 11th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.20). On average, equities research analysts expect that ArriVent BioPharma will post -2.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AVBP. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of ArriVent BioPharma during the 4th quarter valued at approximately $218,000. California State Teachers Retirement System grew its position in shares of ArriVent BioPharma by 561.3% during the 4th quarter. California State Teachers Retirement System now owns 13,649 shares of the company’s stock valued at $364,000 after acquiring an additional 11,585 shares during the period. GAMMA Investing LLC grew its position in shares of ArriVent BioPharma by 3,730.0% during the 1st quarter. GAMMA Investing LLC now owns 2,681 shares of the company’s stock valued at $500,000 after acquiring an additional 2,611 shares during the period. SG Americas Securities LLC lifted its stake in shares of ArriVent BioPharma by 92.1% during the 1st quarter. SG Americas Securities LLC now owns 22,680 shares of the company’s stock valued at $419,000 after buying an additional 10,873 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of ArriVent BioPharma by 6.1% during the 1st quarter. Vanguard Group Inc. now owns 1,503,358 shares of the company’s stock valued at $27,797,000 after buying an additional 86,067 shares in the last quarter. 9.48% of the stock is owned by institutional investors.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.